Belun Ring Platform: a novel home sleep apnea testing system for assessment of obstructive sleep apnea.

STUDY OBJECTIVES: The objective of the study is to validate the performance of Belun Ring Platform, a novel home sleep apnea testing system using a patented pulse oximeter sensor and a proprietary cloud-based neural networks algorithm. METHODS: The Belun Ring captures oxygen saturation, photoplethysmography, and accelerometer signals. The Belun Ring total sleep time is derived from features extracted from accelerometer, oxygen saturation, and photoplethysmography signals. The Belun Ring respiratory event index is derived from Belun Ring total sleep time and features extracted from heart rate variability and oxygen saturation changes. A total of 50 adults without significant cardiopulmonary or neuromuscular comorbidities and heart rate affecting medications were evaluated. In-lab sleep studies were performed simultaneously with the Ring and the studies were manually scored using the American Academy of Sleep Medicine Scoring Manual 4% desaturation criteria. RESULTS: The Belun Ring respiratory event index correlated well with the polysomnography-apnea-hypopnea index (AHI; r = .894, P < .001). The sensitivity and specificity in categorizing AHI ≥ 15 events/h were 0.85 and 0.87, respectively, and the positive predictive value and negative predictive value were 0.88 and 0.83, respectively. The Belun Ring total sleep time also correlated well with the polysomnography-total sleep time (r = .945, P < .001). Although the Belun Ring Platform has a good overall performance, it tends to overestimate AHI in individuals with AHI under 15 events/h and underestimate AHI in those with AHI over 15 events/h. Conclusions: In this proof-of-concept study, the Belun Ring Platform demonstrated a reasonable accuracy in predicting AHI and total sleep time in patients without significant comorbidities and heart rate-affecting medications. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Validation of a Novel Device for Screening Patients With Symptoms of Obstructive Sleep Apnea; URL: https://clinicaltrials.gov/ct2/show/NCT04121923; Identifier: NCT04121923.

Determination of the Dipole Geometry of Fluorescent Nanoparticles Using Polarized Excitation and Emission Analysis.

We demonstrate that the geometries of the absorption dipole µab and emission dipole µem of nano-emitters such as quantum dots can be determined simultaneously by far-field polarimetry. The method involves plotting the emission polarization ratio against the absorption polarization ratio of single nano-emitters. Using Monte Carlo simulation, we show that these plots depend sensitively on the aspect ratio of the dipole shape. For example, the so-called 3D-2D dipole combination, that is, µab of radius ratio 1:1:1 and µem of ratio 1:1:0, would give rise to a vertical line plot. Polarization ratios of commercial cadmium selenide/zinc sulfide (CdSe/ZnS) quantum dots are measured and plotted. The empirical data points are best-fitted to yield µab of radius ratio 1:1:0.28 and µem of ratio 1:1:0.

Measuring the kinetics of the binding of xenoestrogens and estrogen receptor alpha by fluorescence polarization.

The mechanism of endocrine disruption by environmental xenoestrogens is unclear. Bisphenol-A (BPA) is an example. Its concentration in human serum is low, and its binding with estrogen receptor (ER) is weak. Yet its effect on prostate and mammary gland development was observed. We investigated whether this effect could be explained in terms of binding kinetics. We used the method of fluorescence polarization anisotropy to measure the kinetic rate constants of the binding of ERα with 19 xenoestrogens. Relative binding affinities (RBA) were also deduced from the kinetics. We drew three observations. First, our RBAs were consistent with published values, thus establishing the validity of our results. Second, our method allowed the determination of low RBAs (∼ 10(-4)) of lipophilic ligands, such as dibutyl phthalate. They could not be measured by steady-state IC50 assays because of their low solubility. Third, we found that BPA had a surprisingly high kon > 10(4) M(-1) s(-1). While its RBA was 1500 times lower than that of 17ß estradiol (E2), its kon was >1/90 that of E2. As a result, a 10 min surge of BPA from pM to nM could drive the fraction of BPA-activated ERα to a potent 0.1%. This might help to explain the observable estrogenic impacts of BPA.

Measuring binding kinetics of ligands with tethered receptors by fluorescence polarization and total internal reflection fluorescence.

Binding kinetics of nuclear receptors and their specific ligands was measured using polarization anisotropy complemented with total internal reflection fluorescence. Binding affinities of tethered full length human estrogen receptor alpha (ERalpha) with 17beta-estradiol, diethylstilbestrol, raloxifene, 4-hydroxytamoxifen, tamoxifen, and genistein were measured to be 100 (as reference), 100, 35, 21, 8, and 1.5, respectively. They agreed with published results. For the first time, rate constants were measured, and off rates were 1.5, 1.5, 1.3, 1.6, 1.7, and 2.3 x 10(-3) s(-1) while on rates were 11, 10, 3.3, 2.4, 1.0, and 0.26 x 10(5) M(-1)s(-1), respectively. For the antiestrogen drugs, their comparable off-rates correlated well with their equally similar potency. Eleven ginsenosides were screened as potential ligands. None were found to bind to ERalpha, but Rb1(S) and 20(S)-Rg3 were shown to bind to peroxisome proliferator-activated receptor gamma. The latter finding corroborated strongly with the therapeutic effects of ginsenosides on diabetic mice observed in a separate study. Our method would complement surface plasmon resonance assay for small ligands in the mass range of tens to hundreds of Daltons.